Predicted protein targets (top 11)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | HTR1D | P28221 | 2/20 | 0.38 |
| ▸ | REN | P00797 | 13/20 | 0.37 |
| ▸ | HTR7 | P34969 | 1/20 | 0.35 |
| ▸ | HPGD | P15428 | 1/20 | 0.35 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.35 |
| ▸ | MTNR1A | P48039 | 1/20 | 0.35 |
| ▸ | MTNR1B | P49286 | 1/20 | 0.35 |
| ▸ | PTGS2 | P35354 | 1/20 | 0.35 |
| ▸ | TRPV1 | Q8NER1 | 1/20 | 0.35 |
| ▸ | HTR1B | P28222 | 1/20 | 0.35 |
| ▸ | SPR | P35270 | 1/20 | 0.35 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL4539260 | 1.00 | HTR1D (0.38) | HTR1DRENHTR7HPGDCYP2C19 | |
| Hydrochloric Acid SCHEMBL5164080 | 0.85 | HTR1D (0.40) | HTR1DHTR7CYP2C19MTNR1AMTNR1B | |
| SCHEMBL1049543 | 0.84 | HTR1D (0.39) | HTR1DHTR7CYP2C19MTNR1AMTNR1B | |
| SCHEMBL4525603 | 0.84 | REN (0.36) | REN | |
| Hydrochloric Acid SCHEMBL1049681 | 0.84 | HTR1D (0.39) | HTR1DHTR7CYP2C19MTNR1AMTNR1B | |
| Hydrochloric Acid SCHEMBL1050543 | 0.83 | TRPV1 (0.36) | HTR1DRENHPGDMTNR1AMTNR1B | |
| Hydrochloric Acid SCHEMBL1048916 | 0.82 | HTR1D (0.36) | HTR1DMTNR1AMTNR1BPTGS2TRPV1 | |
| SCHEMBL1047567 | 0.81 | HTR1D (0.39) | HTR1DHTR7HPGDCYP2C19MTNR1A | |
| Hydrochloric Acid SCHEMBL1051875 | 0.79 | HTR1D (0.38) | HTR1DRENHTR1B | |
| SCHEMBL1049084 | 0.78 | KMT2A (0.38) | HTR1DHPGDMTNR1AMTNR1BPTGS2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 8 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-7851634-B2 | 5-amino 4-hydroxy-7-(1H-indolmethyl)-8-methylnonamide derivatives as renin inhibitors for the treatment of hypertension | NOVARTIS AG (CH) | 2010-12-14 | — | — | US | disclosed |
| EP-1717226-B1 | 2,7-SUBSTITUTED 5-AMINO-4-HYDROXY-8-(1H-INDOL-5-YL)-OCTAN AMIDE DERIVATIVES AS RENIN INHIBITORS FOR THE TREATMENT OF HYPERTENSION | SPEEDEL EXPERIMENTA AG (CH) | 2009-01-21 | — | — | EP | disclosed |
| US-20080280895-A1 | 5-Amino-4-Hydroxy-7-(1H-Indolmethyl)-8-Methylnonamide Derivatives as Renin Inhibitors for the Treatment of Hypertension | NOVARTIS AG (CH) | 2008-11-13 | — | — | US | disclosed |
| US-20070066604-A1 | Diaminoalcohols as therapeutic compounds | SPEEDEL EXPERIMENTA AG (CH) | 2007-03-22 | — | — | US | disclosed |
| EP-1764098-A1 | Diaminoalcohols derivatives for the treatment of Alzheimer, malaria, HIV | Speedel Experimenta AG (CH) | 2007-03-21 | — | — | EP | disclosed |
| EP-1724259-A1 | 2,7-SUBSTITUTED 5-AMINO-4-HYDROXY-8-(1H-INDAZOL-5-YL)-OCTAN AMIDE DERIVATIVES AND RELATED COMPOUNDS AS RENIN INHIBITORS FOR THE TREATMENT OF HYPERTENSION | Speedel Experimenta AG (CH) | 2006-11-22 | — | — | EP | disclosed |
| EP-1717226-A1 | 2,7-SUBSTITUTED 5-AMINO-4-HYDROXY-8-(1H-INDOL-5-YL)-OCTAN AMIDE DERIVATIVES AS RENIN INHIBITORS FOR THE TREATMENT OF HYPERTENSION | Speedel Experimenta AG (CH) | 2006-11-02 | — | — | EP | disclosed |
| EP-1712548-A2 | 5-AMINO-4-HYDROXY-7-(PYRIDINYLMETHYL)-ALKANAMIDE DERIVATIVES AND RELATED COMPOUNDS AS RENIN INHIBITORS FOR THE TREATMENT OF HYPERTENSION | Speedel Experimenta AG (CH) | 2006-10-18 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20070066604-A1 | Diaminoalcohols as therapeutic compounds | CTSD, FURIN, CTSL | HTR1D 1623/4885REN 161/4885HTR7 3480/4885 |
| US-20080280895-A1 | 5-Amino-4-Hydroxy-7-(1H-Indolmethyl)-8-Methylnonamide Derivatives as Renin Inhibitors for the Treatment of Hypertension | REN, AGTR1, AGTR2 | HTR1D 197/4885REN 1/4885HTR7 66/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.